UCD spin-out developing the OncoMasTR early-stage breast cancer test.
| Date | Round | Amount |
|---|---|---|
| Mar 2021 | Acquired by Cepheid US molecular diagnostics firm Cepheid acquired UCD spin-out OncoMark, maker of the OncoMasTR breast cancer test, for an undisclosed sum; the deal closed in March 2021 and was disclosed publicly in December. | — |